Progressions 2007: The Ernst & Young Global Pharmaceutical Report

Product safety is a leading concern in the pharmaceutical industry — and the focus of "Progressions 2007", which shows how drug safety is more than just a compliance issue.

As pharmaceutical executives entered the twenty-first century, they were bracing for the long list of patent expirations, increasing research and development costs, and pricing pressures. No one could have imagined, however, the degree of public outcry over drug safety standards and the resulting increase in regulatory requirements.

The challenge facing the industry now is not only that two major fault lines — safety expectations and the business model — have shifted concurrently, but that the resulting whirlpool of making products safer while trying to create the next great innovations has curtailed the industry’s ability to grow and deliver new medicines at the rate it has done so in the past. How should companies invest resources to both build stakeholder confidence and enhance the bottom line?

Read more about the top-of-mind issues in "Progressions 2007" and request your copy today.

Progressions 2007 Highlights

Benefits of RMPs lag behind problems
A high percentage of deficient risk management plans (RMPs) identified in a sample examined by the EMEA reveal implementation challenges with the European Union’s RMP. To date, questions about why and how are more prominent than answers regarding the benefits of submitting an RMP. “Europe’s risk management plans — beyond pharmacovigilance” suggests an approach and guiding questions that may help companies meet the mark.

Avoiding value destruction
The sheer pace of global deal-making in the pharma industry can leave acquisitions and alliances vulnerable to risks that were overlooked in due diligence. Rather than creating value, some transactions may destroy it. “On the safe side of deals,” suggests a holistic approach to how executives can balance the speed at which they conduct transactions and the need to investigate potential risks.

Protecting your product’s reputation
Pharmaceutical manufacturers seeking protection against product theft, counterfeiting, and fraud must fundamentally rethink and integrate their risk processes and strategies to encompass each step of the product life cycle. “Protecting product integrity” highlights an emerging approach to product protection — one that is integrated, comprehensive, and enterprise-wide.

Table of contents

Browse the full listing of articles from "Progressions 2007". You'll also find three articles from the report that are available for download.

Industry leaders contribute to Progressions 2007

"Progressions 2007" brings together Ernst & Young industry professionals and leading thinkers from virtually every sector of health sciences to give you broad perspectives and deep knowledge of the pharmaceutical industry. View the full list of contributing authors and participants.

Compliance, drug safety, supply chain performance and more

The Global Pharmaceutical Center invites you to learn more about the issues facing the pharmaceutical industry by listening to our podcast series. Each podcast focuses on a topic from "Progressions 2007" such as product safety, compliance, harnessing valuable data analysis, and improving supply chain performance by partnering with Customs to stop counterfeit products.

"Progressions" to increase yearly issues

After publishing four annual issues of "Progressions" since 2003, the Ernst & Young Global Pharmaceutical Center will now be providing this premier thought leadership report twice a year to offer timely insights and perspectives on the key issues on your minds.